Table 2.
Baseline characteristics of studies included in the adjuvant therapy for curatively resected gastric cancer network meta-analysis (NMA-2).
| Studies | No. | Regimen | Node | Stage 1 | D2 or > LND No. (%) | Descent | Age, Median, (Range), y | Men No. (%) |
|---|---|---|---|---|---|---|---|---|
| Anthracycline + Fluoropyrimidine vs. Observation | ||||||||
| Neri 2001 [24] | 69 | Epi + 5-FU/Lv | AF | II–III | 9 (13) | W | 62 (37–73) | 50 (72.5) |
| 68 | Observation | Obs | II–III | 10 (15) | W | 64 (35–74) | 48 (70.6) | |
| Krook 1991 [25] | 61 | Doxo + 5-FU | AF | I–III | NR | W | 63 (33–77) | 47 (77) |
| 64 | Observation | Obs | I–III | NR | W | 62 (38–78) | 51 (80) | |
| Anthracycline + Doublet vs. Observation | ||||||||
| Kulig 2010 [26] | 141 | Doxo + Eto + Cis | ATr | I–III | 112 (79) | W | 61 (58–67) | 100 (71) |
| 154 | Observation | Obs | I–III | 123 (80) | W | 64 (61–66) | 111 (72) | |
| Di Costanzo 2008 [27] | 130 | Epi + Cis + 5-FU/Lv | ATr | I–III | 71 (55) | W | 59 | 79 (61) |
| 128 | Observation | Obs | I–III | 72 (56) | W | 59 | 78 (61) | |
| De Vita 2007 [28] | 112 | Epi + Eto + 5-FU/Lv | ATr | I–III | 0 | W | 63 (39–70) | 66 (59) |
| 113 | Observation | Obs | I–III | 0 | W | 62 (41–70) | 65 (58) | |
| Tentes 2006 [29] | 20 | Doxo + MMC + 5-FU | ATr | II–III | 20 (100) | W | 65 (±10) * | 14 (70) |
| 20 | Observation | Obs | II–III | 20 (100) | W | 65 (±11) * | 11 (55) | |
| Tsavaris 1996 [30] | 42 | Epi + MMC + 5-FU | ATr | III | NR | W | 53 (41–65) * | 32 (76) |
| 42 | Observation | Obs | III | NR | W | 57 (35–66) * | 25 (60) | |
| Lise 1995 [31] | 155 | Doxo + MMC + 5-FU | ATr | II–III | 84 (27) | W | <71 years | 94 (61) |
| 159 | Observation | Obs | II–III | W | <71 years | 108 (68) | ||
| Coombes 1990 [32] | 133 | Doxo + MMC + 5-FU | ATr | II–III | NR | W | 57 * | 93 (70) |
| 148 | Observation | Obs | II–III | NR | W | 57 * | 98 (68) | |
| Anthracycline + Etoposide + Cisplatin + Fluoropyrimidine vs. Observation | ||||||||
| Bajetta 2002 [33] | 135 | Doxo + Eto + Cis + 5-FU/Lv | AECF | II–III | Maj. | W | 57 (23–70) | 81 (59) |
| 136 | Observation | Obs | II–III | Maj. | W | 57 (31–70) | 93 (68) | |
| Anthracycline + Doublet vs. Fluoropyrimidine | ||||||||
| Cascinu 2007 [34] | 201 | Epi + Cis + 5-FU/Lv | ATr | II–III | 312 (79) | W | 58 | 135 (67) |
| 196 | 5FU/Lv | F | II–III | W | 59 | 120 (61) | ||
| Lee 2004 [35] | 32 | Epi + Cis + 5-FU/Lv | ATr | III | 32 (100) | A | 53 (31–61) | 13 (41) |
| 29 | 5-FU | F | III | 29 (100) | A | 52 (26–66) | 13 (45) | |
| Anthracycline + Fluoropyrimidine vs. Mitomycin C + Fluoropyrimidine vs. Fluoropyrimidine | ||||||||
| Tsujinaka 2000 [36] | 61 | Epi + 5-FU | AF | I–II | 60 (98) | A | ≤75 years | 38 (62) |
| 62 | MMC + 5-FU | MF | I–II | 61 (98) | A | ≤75 years | 44 (71) | |
| 62 | 5-FU | F | I–II | 61 (98) | A | ≤75 years | 44 (71) | |
| Anthracycline + Doublet vs. Mitomycin C + Fluoropyrimidine vs. Fluoropyrimidine | ||||||||
| Chang 2002 [37] | 131 | Doxo + MMC + 5-FU | ATr | I–III | 131 (100) | A | 51 (26–70) | 100 (76) |
| 131 | MMC + 5-FU | MF | I–III | 131 (100) | A | 54 (23–74) | 96 (73) | |
| 133 | 5-FU | F | I–III | 133 (100) | A | 53 (21–75) | 99 (74) | |
| Cisplatin + Fluoropyrimidine vs. Observation | ||||||||
| Bouche 2005 [38] | 127 | Cis + 5-FU | CF | II–III | 70 (27) | W | 60 (32–82) | 93 (73) |
| 133 | Observation | Obs | II–III | W | 62 (31–83) | 93 (70) | ||
| Chipponi 2004 [39] | 93 | Cis + 5-FU/Lv | CF | II–III | D1+D2 | W | 59 * | 58 (62) |
| 103 | Observation | Obs | II–III | W | 63 * | 71 (69) | ||
| Fluoropyrimidine vs. Observation | ||||||||
| Sasako 2011 [40] | 529 | S-1 | F | II–III | 529 (100) | A | 63 (27–80) | 367 (69) |
| 530 | Observation | Obs | II–III | 530 (100) | A | 63 (33–80) | 369 (70) | |
| Nakajima 2007 [41] | 93 | UFT | F | II–III | 93 (100) | A | 63 | 75 (70) |
| 95 | Observation | Obs | II–III | 95 (100) | A | 64 | 77 (73) | |
| Mitomycin C vs. Observation | ||||||||
| Grau 1993 [42] | 68 | MMC | M | I–III | NR | W | 56 * | 44 (65) |
| 66 | Observation | Obs | I–III | NR | W | 57 * | 44 (67) | |
| Mitomycin C + Fluoropyrimidine vs. Observation | ||||||||
| Cirera 1999 [43] | 76 | MMC + Tgf | MF | I–III | 76 (100) | W | 61 * | 52 (68) |
| 72 | Observation | Obs | I–III | 72 (100) | W | 61 * | 42 (58) | |
| Kim 1992 [44] | 77 | MMC + 5-FU | MF | III | 77 (100) | A | (30–70) | NR |
| 94 | Observation | Obs | III | 94 (100) | A | (30–70) | NR | |
| Mitomycin C + Fluoropyrimidine vs. Mitomycin C | ||||||||
| Grau 1998 [45] | 40 | MMC + Tgf | MF | I–III | D1+D2 | W | 62 (36–75) | 27 (68) |
| 45 | MMC | M | I–III | W | 63 (22–75) | 27 (60) | ||
| Mitomycin C + Cisplatin + Fluoropyrimidine vs. Mitomycin C + Fluoropyrimidine | ||||||||
| Kang 2013 [46] | 431 | MMC + Cis + 5DFUR | MCF | II–III | 431 (100) | A | 55 (20–70) | 294 (68) |
| 424 | MMC + 5DFUR | MF | II–III | 424 (100) | A | 56 (29–70) | 294 (69) | |
| Mitomycin C + Cisplatin + Fluoropyrimidine vs. Cisplatin + Fluoropyrimidine | ||||||||
| Shimoyama 1999 [47] | 12 | MMC + Cis + UFT (600 mg) | MCF | I–III | D1+D2 | A | 65 (±8) | 13 (77) |
| 17 | Cis + UFT | CF | I–III | A | 64 (±8) | 8 (67) | ||
| Oxaliplatin + Fluoropyrimidine vs. Observation | ||||||||
| Noh 2014 [48] | 520 | Ox + Cap | OxF | II–III | 520 (100) | A | 56 (±11) * | 373 (72) |
| 515 | Observation | Obs | II–III | 515 (100) | A | 56 (±11) * | 358 (70) | |
| Oxaliplatin + Fluoropyrimidine vs. Fluoropyrimidine | ||||||||
| Zhang 2011 [49] | 42 | Ox + 5-FU/Lv | OxF | II–III | 42 (100) | A | 48 | 25 (60) |
| 38 | 5-FU/Lv | F | II–III | 38 (100) | A | 54 | 24 (63) | |
| Oxaliplatin + Fluoropyrimidine Prolonged vs. Oxaliplatin + Fluoropyrimidine | ||||||||
| Feng 2015 [50] | 152 | Ox + Cap (Prolonged) | OxFPr | II–III | 152 (100) | A | 61 (±11) | 104 (67) |
| 155 | Ox + Cap | OxF | II–III | 155 (100) | A | 60 (±10) | 99 (65) | |
| Radiotherapy + Chemotherapy vs. Observation | ||||||||
| Smalley 2012 [6] | 281 | RT + 5-FU/Lv | RCh | I–III | 54 (10) | W | 60 (25–87) | 202 (72) |
| 275 | Observation | Obs | I–III | W | 59 (23–80) | 195 (71) | ||
| Radiotherapy + Chemotherapy vs. Fluoropyrimidine | ||||||||
| Kim 2012 [51] | 46 | RT + 5-FU/Lv | RCh | III | 46 (100) | A | 9> 60 | 34 (74) |
| 44 | 5-FU/Lv | F | III | 44 (100) | A | 14>60 | 25 (57) | |
| Yu 2012 [52] | 34 | RT + 5-FU/Lv | RCh | II–III | D1+D2 | A | NR | NR |
| 34 | 5-FU/Lv | F | II–III | A | NR | NR | ||
| Zhu 2012 [53] | 186 | RT + 5-FU/Lv | RCh | I–III | 205 (100) | A | 56 (38–73) | 135 (73) |
| 165 | 5-FU/Lv | F | I–III | 175 (100) | A | 59 (42–75) | 126 (76) | |
| Radiotherapy + Chemotherapy vs. Cisplatin + Fluoropyrimidine | ||||||||
| Park 2015 [54] | 230 | RT + Cis + Cap | RCh | I–III | 230 (100) | A | 56 (28–76) | 143 (62) |
| 228 | Cis + Cap | CF | I–III | 228 (100) | A | 56 (22–77) | 153 (67) | |
| Kwon 2010 [55] | 31 | RT + Cis + Cap + 5-FU | RCh | III | 31 (100) | A | 8 ≥ 60 | 21 (68) |
| 30 | Cis + 5-FU | CF | III | 30 (100) | A | 14 ≥ 60 | 23 (77) | |
| Radiotherapy + Chemotherapy vs. Taxane + Cisplatin | ||||||||
| Bamias 2010 [56] | 72 | RT + Dtx + Cis/Car | RCh | II–III | D0+D1+D2 | W | 63 (32–75) | 48 (67) |
| 71 | Dtx + Cis/Car | TC | II–III | W | 62 (41–79) | 52 (73) | ||
| Taxane + Fluoropyrimidine vs. Cisplatin + Fluoropyrimidine | ||||||||
| Lee 2016 [57] | 75 | Dtx + S-1 | TF | III | 75 (100) | A | NR | NR |
| 78 | Cis + S-1 | CF | III | 78 (100) | A | NR | NR | |
| Taxane + Irinotecan + Cisplatin + Fluoropyrimidine vs. Fluoropyrimidine or Mitomycin C | ||||||||
| Bajetta 2014 [58] | 562 | Dtx + IRI + Cis + 5-FU/Lv | TICF | II–III | 796 (72) | W | ≤75 years | NR |
| 538 | 5-FU/Lv | F | II–III | W | ≤75 years | NR | ||
| Di Bartolomeo 2006 [59] | 85 | Dtx + IRI + Cis + 5-FU/Lv | TICF | II–III | 66 (77) | W | 10 ≥ 70 | 60 (71) |
| 81 | MMC | M | II–III | 62 (76) | W | 8 ≥ 70 | 55 (68) | |
1 Staging was done according to the 7th edition of the AJCC and according to the pathological TNM stage [23]. * Mean age was given instead of median age. Abbreviations: 5-DFUR = doxifluridine; 5-FU = 5-fluorouracil; A = anthracycline; A descent = Asian; ATr = anthracycline-based triplet; Cap = capecitabine; Car = carboplatin; C = cisplatin; Cis = cisplatin; Doxo = doxorubicin; Dtx = docetaxel; E = etoposide; Epi = epirubicin; Eto = etoposide; F = fluoropyrimidine; I = irinotecan; IRI = irinotecan; LND = lymph node dissection; Lv = leucovorin; M = mitomycin C; MMC = mitomycin C; No. = number; NR = not reported; Obs = observation; Ox = oxaliplatin; OxFpr = doublet oxaliplatin with an one year treatment with a fluoropyrimidine; RT = radiotherapy; RCh = chemoradiotherapy; T = taxane; Tgf = tegafur; UFT = uracil/tegafur; W = western; y = years.